PYC THERAPEUTICS LIMITED — Board/Management Information 2017

Oct 24, 2017

Establishment and appointments to Scientific Advisory Board

PERTH, Australia, 25th October 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to announce the establishment of and first appointments to a scientific advisory board (SAB).

The newly appointed SAB will serve as a strategic resource for Phylogica as the Company continues to develop its drug delivery platform technology, harnessing its ability to carry drug cargoes inside cells as new generation therapies for a range of diseases.

The first members of Phylogica's SAB are:

• Prof. Judy Lieberman
  • o Chair in Cellular and Molecular Medicine at Boston Children's Hospital & Professor of Pediatrics, Harvard Medical School

Dr. Stephen Doberstein

o Senior Vice President and Chief Scientific Officer of Nektar Therapeutics

Full biographies for each member of the Phylogica SAB are available below.

Commenting on appointments to the Phylogica SAB, CEO Stephanie Unwin said, "We are pleased with the addition of these experts in intracellular delivery and disease biology to complement our internal research team. The background and experience these two members bring will be invaluable as we look to commercialize our platform and also work on delivering commercial products into the intracellular environment where important unexploited disease targets are located."

Dr. Rob Hayes, Phylogica's CSO said, "It is a testament to the potential of our platform that these two experts have agreed to join our SAB. Judy is a well-known expert in the field of intracellular delivery. She will help us mature and apply our FPP technology to a range of therapeutic cargoes and cell types. Steve is a disease biology expert with a remarkably productive record of putting molecules into the clinic, in therapeutic areas ranging from pain to immuno-oncology.

The SAB will meet on a quarterly basis, and ad hoc as needed, as we develop our intracellular delivery platform against a range of therapeutic targets."

Biographies

Prof. Judy Lieberman

Judy Lieberman, MD, Ph.D, holds a Chair in Cellular and Molecular Medicine at Boston Children's Hospital, is Professor of Pediatrics at Harvard Medical School and is Chair of the Executive Committee of Immunology at Harvard Medical School. She earned a Ph.D. in theoretical physics from Rockefeller University and worked as a theoretical physicist at the Institute for Advanced Study in Princeton and Fermilab, received an M.D. from Harvard and MIT, did a postdoctoral fellowship in immunology in the Cancer Center at MIT and worked as a hematologist/oncologist at Tufts Medical Center.

Her laboratory has been in the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening. They were the first to show that siRNAs could be used to treat disease in vivo and to develop cell-targeted RNAs.

The Leiberman laboratory has developed strategies for cell-specific siRNAs that knockdown gene expression in vivo in T lymphocytes and cancer cells. They also investigate the role of microRNAs in regulating cell differentiation and cancer. This laboratory also studies cytotoxic T lymphocytes and their role in immune protection from infection and cancer.

Dr. Lieberman served as the Chair of the Medical Sciences section and on the Council of the American Association for the Advancement of Sciences. She has received numerous awards for her research on vaccines, immunology and cancer. She is a member of the American Academy of Arts and Sciences.

Dr Stephen Doberstein

Steve Doberstein joined Nektar Therapeutics in January 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of the company's drug discovery research.

Dr. Doberstein has over 17 years of experience in biotechnology research and development, and prior to joining Nektar Therapeutics was Vice President of Research at XOMA (NASDAQ:XOMA) where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/ pharmacodynamics.

Dr. Doberstein also served as Vice President, Research at Five Prime Therapeutics (NASDAQ:FPRX), a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group.

While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to working with Five Prime,

Dr. Doberstein was Vice President, Research at Xencor (NASDAQ:XNCR), an antibody and protein engineering and development company. At Xencor, he was instrumental in advancing its protein platform technologies and preclinical product candidates.

Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.

ENDS

For further information, please contact:

INVESTORS MEDIA Stephanie Unwin CEO stephanieu@phylogica.com 0411 132 287

Ben Walsh WE Buchan bwalsh@buchanwe.com.au 0411 520 012

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell membranes to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genentech.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801 www.phylogica.com Phylogica Ltd ABN 48 098 391 961